In this study, 35 patients were treated with PC chemotherapy. The study has been completed, analyzed, and published (Herrlinger et al., Ann Neurol 70:445-453,2011). With PC therapy alone, median progression-free survival was 14 months, and median overall survival was 30 months. Detection of an IDH-1 mutation and the absence of a bihemispheric symmetric growth pattern on MRI were found to be independent positive prognostic factors in a multivariate analysis. The NOA-05 study is the only prospective therapeutic study in gliomatosis cerebri to date and establishes PC therapy alone as a reasonable first-line treatment for gliomatosis cerebri.